{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sheng L"],"funding":["Samuel Waxman Cancer Research Foundation","National Natural Science Foundation of China"],"pagination":["790720"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8882913"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["<h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma and related to autoimmune diseases (AIDs). Primary B-cell receptor-mediated AIDs are associated with poor clinical outcome of DLBCL. To further determine the role of immunological alterations on disease progression, our study integrated genomic and transcriptomic analyses on DLBCL with multiple abnormal immunologic markers.<h4>Methods</h4>The clinical data of 1,792 patients with newly diagnosed DLBCL were collected, with DNA- and RNA-sequencing conducted for 164 and 127 patients, respectively. Frequent gene mutations and the involved dysregulated pathways, along with gene expression pattern and tumor microenvironment alternations, were analyzed and compared based on the immune status of the "],"journal":["Frontiers in oncology"],"pubmed_title":["Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers."],"pmcid":["PMC8882913"],"funding_grant_id":["81830007, 82070204, 81670176"],"pubmed_authors":["Cheng S","Fu D","Xu P","Sheng L","Huo Y","Wang S","Cao Y","Zhao W","Shen R","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers.","description":"<h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma and related to autoimmune diseases (AIDs). Primary B-cell receptor-mediated AIDs are associated with poor clinical outcome of DLBCL. To further determine the role of immunological alterations on disease progression, our study integrated genomic and transcriptomic analyses on DLBCL with multiple abnormal immunologic markers.<h4>Methods</h4>The clinical data of 1,792 patients with newly diagnosed DLBCL were collected, with DNA- and RNA-sequencing conducted for 164 and 127 patients, respectively. Frequent gene mutations and the involved dysregulated pathways, along with gene expression pattern and tumor microenvironment alternations, were analyzed and compared based on the immune status of the ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T08:57:24.863Z","creation":"2025-04-04T08:57:24.863Z"},"accession":"S-EPMC8882913","cross_references":{"pubmed":["35237512"],"doi":["10.3389/fonc.2022.790720"]}}